Guinea-Bissau Cancels US-Funded Hepatitis B Vaccine Trial Amid Ethical Backlash
A controversial study involving 14,000 newborns was halted following allegations of unethical research practices.
1Trial Cancellation and Controversy
Guinea-Bissau authorities have officially cancelled a proposed hepatitis B vaccine trial involving 14,000 newborns. The project, funded by the US government under Health Secretary Robert F. Kennedy Jr., faced intense international criticism. Police have seized vaccine batches from the Bandim Health Project, a research center operating in the country since 1978.
2Ethical Concerns Over Methodology
The study design drew condemnation for planning to withhold a World Health Organization-recommended vaccine from half of the participating infants. Critics argued this approach was unethical, as the vaccine has been proven effective for over 30 years. Experts questioned why such high-risk research was targeted at a vulnerable population in Guinea-Bissau.
3High Infection Risks Locally
Nearly one-fifth of the population in Guinea-Bissau is infected with hepatitis B, a viral condition that causes severe liver damage. Infants are at extreme risk of chronic infection, which can lead to liver failure or cancer. Currently, the country only administers the vaccine at six weeks, reducing its overall protective efficacy.
4Conflicting Claims on Approval
The University of Southern Denmark, which received $1.6 million from the CDC for the study, claimed they obtained local ethical approval. However, Health Minister Quinhin Nantote explicitly denied this, expressing outrage that the government was not informed. The ministry maintains that a January prohibition on pediatric vaccine trials remains in full force.
5Neocolonialism and Research Ethics
Global health experts, including Professor Gavin Yamey, labeled the proposal as neocolonial. Critics highlighted the disparity in research standards, questioning why the trial was not conducted in Denmark instead of one of the world's poorest nations. The debate underscores broader concerns about the exploitation of vulnerable populations in international medical research.
6WHO and Government Intervention
The WHO representative in Guinea-Bissau, Walter Kazadi Mulombo, raised alarms after discovering the study lacked a publicly available protocol. The organization is now working with the government to accelerate the introduction of the birth-dose vaccine. Officials are considering moving the national rollout date from 2028 to early next year.
7University Defense and Status
Jakob Grauslund, dean at the University of Southern Denmark, stated that the trial never commenced and no babies were enrolled. The institution maintains it received a positive assessment from its own internal research ethics committee. Despite these claims, the local government remains firm in its decision to halt all related activities.
8Future Implications for Research
This incident highlights the critical importance of transparency and local oversight in global health trials. The seizure of materials and the government's firm stance reflect a growing demand for ethical accountability. Future research in the region will likely face stricter scrutiny to ensure that international standards protect local participants from harm.